Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Depreciation & Amortization (CF) (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $7.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 121.88% to $7.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $28.0 million, a 108.15% increase, with the full-year FY2024 number at $14.5 million, up 14.46% from a year prior.
  • Depreciation & Amortization (CF) was $7.9 million for Q3 2025 at Usana Health Sciences, up from $7.7 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $8.3 million in Q1 2025 to a low of $2.5 million in Q1 2022.
  • A 5-year average of $4.1 million and a median of $3.3 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): dropped 11.54% in 2023, then skyrocketed 164.06% in 2025.
  • Usana Health Sciences' Depreciation & Amortization (CF) stood at $3.2 million in 2021, then rose by 1.89% to $3.3 million in 2022, then dropped by 11.54% to $2.9 million in 2023, then skyrocketed by 37.33% to $4.0 million in 2024, then skyrocketed by 98.02% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Depreciation & Amortization (CF) are $7.9 million (Q3 2025), $7.7 million (Q2 2025), and $8.3 million (Q1 2025).